Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers

被引:51
|
作者
Aparicio, Hugo J. [1 ,2 ]
Carr, Brendan G. [5 ]
Kasner, Scott E. [2 ]
Kallan, Michael J. [3 ]
Albright, Karen C. [6 ,7 ,8 ]
Kleindorfer, Dawn O. [9 ]
Mullen, Michael T. [2 ,4 ]
机构
[1] Boston Univ, Dept Neurol, Boston, MA 02215 USA
[2] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[5] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA
[6] Univ Alabama Birmingham, Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL USA
[7] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL USA
[8] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA
[9] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
health disparities; health policy; stroke; stroke care; thrombolysis; ACUTE ISCHEMIC-STROKE; CERTIFIED PRIMARY STROKE; AMERICAN-HEART-ASSOCIATION; MEDICAL-SERVICES USE; ETHNIC DISPARITIES; TEMPORAL TRENDS; UNITED-STATES; RISK-FACTORS; OUTCOMES; EMERGENCY;
D O I
10.1161/JAHA.115.001877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Primary stroke centers (PSCs) utilize more recombinant tissue plasminogen activator (rt-PA) than non-PSCs. The impact of PSCs on racial disparities in rt-PA use is unknown. Methods and Results-We used data from the Nationwide Inpatient Sample from 2004 to 2010, limited to states that publicly reported hospital identity and race. Hospitals certified as PSCs by The Joint Commission were identified. Adults with a diagnosis of ischemic stroke were analyzed. Rt-PA use was defined by the International Classification of Diseases, 9th Revision procedure code 99.10. Discharges (304 152 patients) from 26 states met eligibility criteria, and of these 71.5% were white, 15.0% black, 7.9% Hispanic, and 5.6% other. Overall, 24.7% of white, 27.4% of black, 16.2% of Hispanic, and 29.8% of other patients presented to PSCs. A higher proportion received rt-PA at PSCs than non-PSCs in all race/ethnic groups (white 7.6% versus 2.6%, black 4.8% versus 2.0%, Hispanic 7.1% versus 2.4%, other 7.2% versus 2.5%, all P<0.001). In a multivariable model adjusting for year, age, sex, insurance, medical comorbidities, a diagnosis-related group-based mortality risk indicator, ZIP code median income, and hospital characteristics, blacks were less likely to receive rt-PA than whites at non-PSCs (odds ratio=0.58, 95% CI 0.50 to 0.67) and PSCs (odds ratio=0.63, 95% CI 0.54 to 0.74) and Hispanics were less likely than whites to receive rt-PA at PSCs (odds ratio=0.77, 95% CI: 0.63 to 0.95). In the fully adjusted model, interaction between race and presentation to a PSC for likelihood of receiving rt-PA did not reach significance (P=0.98). Conclusions-Racial disparities in intravenous rt-PA use were not reduced by presentation to PSCs. Black patients were less likely to receive thrombolytic treatment than white patients at both non-PSCs and PSCs. Hispanic patients were less likely to be seen at PSCs relative to white patients and were less likely to receive intravenous rt-PA in the fully adjusted model.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [1] Racial and Ethnic Disparities in the Use of Intravenous Recombinant Tissue Plasminogen Activator and Outcomes for Acute Ischemic Stroke
    Nasr, Deena M.
    Brinjikji, Waleed
    Cloft, Harry J.
    Rabinstein, Alejandro A.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2013, 22 (02): : 154 - 160
  • [2] Racial and Ethnic disparities in the use of intravenous recombinant tissue plasminogen activator(rtPA) and outcomes for acute ischaemic stroke.
    Geraghty, O. C.
    Venter, M.
    Kar, A.
    Ames, D.
    CEREBROVASCULAR DISEASES, 2014, 37 : 680 - 680
  • [3] The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke
    Kahn, JH
    Viereck, J
    Kase, C
    Jeerakathil, T
    Romero, R
    Mehta, SD
    Kociol, R
    Babikian, V
    JOURNAL OF EMERGENCY MEDICINE, 2005, 29 (03): : 273 - 277
  • [4] Ethnic disparities in the use of intravenous recombinant tissue plasminogen activator(rtPA) and outcomes for acute ischaemic stroke.
    Geraghty, O. C.
    Venter, M.
    Kar, A.
    Ames, D.
    CEREBROVASCULAR DISEASES, 2014, 37 : 680 - 680
  • [5] A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset
    Balogun, Ibrahim O.
    Brown, Aaron
    Bertoni, Miguel
    Webb, Thomas
    Hargroves, David
    Pullicino, Patrick
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (08): : 1843 - 1850
  • [6] Update on Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
    Fugate, Jennifer E.
    Rabinstein, Alejandro A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (07) : 960 - 972
  • [7] Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke
    Wiese, Kathleen M.
    Talkad, Arun
    Mathews, Maureen
    Wang, David
    STROKE, 2006, 37 (08) : 2168 - 2169
  • [8] Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban
    De Smedt, Ann
    Cambron, Melissa
    Nieboer, Koenraad
    Moens, Maarten
    Van Hooff, Robbert-Jan
    Yperzeele, Laetitia
    Jochmans, Kristin
    De Keyser, Jacques
    Brouns, Raf
    INTERNATIONAL JOURNAL OF STROKE, 2014, 9 (07) : E31 - E31
  • [9] Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran
    De Smedt, Ann
    De Raedt, Sylvie
    Nieboer, Koenraad
    De Keyser, Jacques
    Brouns, Raf
    CEREBROVASCULAR DISEASES, 2010, 30 (05) : 533 - 534
  • [10] Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban
    Ishihara, Hideyuki
    Torii, Hiroaki
    Imoto, Hirochika
    Oka, Fumiaki
    Sadahiro, Hirokazu
    Suzuki, Michiyasu
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2014, 23 (10): : E457 - E459